Enzymes Indicative of Heart Diseases: Diagnostic Importance

When someone experiences a heart attack, their heart muscle suffers damage. As cells break down, they release specific enzymes into the bloodstream. Measuring these enzymes has become one of the most reliable ways to diagnose heart diseases like myocardial infarction. Understanding which enzymes matter and when they appear can mean the difference between timely treatment and serious complications.

The evolution of cardiac enzyme testing 🔗

The history of cardiac enzyme testing began in 1954 when researchers discovered that Aspartate Aminotransferase (AST) levels increased after a heart attack. This groundbreaking finding launched the era of biochemical markers for heart disease diagnosis. AST rises within 3 to 4 hours after myocardial injury, peaks at 15 to 28 hours, and returns to normal within 5 days. However, doctors soon realized AST wasn’t specific enough for heart tissue alone, as it also increases with liver disease, pulmonary embolism, and other conditions.

Just one year later, Lactate Dehydrogenase (LDH) emerged as another potential biomarker. LDH increases within 6 to 12 hours after a heart attack, peaks within 24 to 72 hours, and normalizes within 8 to 14 days. While LDH offered a longer detection window, it shared the same problem as AST: it appears in many organs including skeletal muscle, kidney, liver, and red blood cells. This lack of specificity meant elevated LDH could indicate various conditions beyond heart damage.

Creatine kinase: the game changer 🔗

The introduction of Creatine Kinase (CK) testing in the 1970s significantly improved cardiac diagnosis. CK exists as three different forms based on two subunits (M and B): CK-MM found in skeletal muscle, CK-BB in the brain, and CK-MB primarily in heart muscle. Since about 20% of total CK in heart muscle exists as CK-MB, this isoenzyme became much more specific for detecting cardiac damage.

How CK-MB works in diagnosis 🔗

CK-MB becomes detectable in blood 4 to 6 hours after myocardial injury, peaks around 24 hours, and returns to baseline within 48 to 72 hours. This relatively quick normalization makes CK-MB particularly useful for detecting a second heart attack when previous damage has already occurred. Doctors often calculate a CK-MB relative index by dividing CK-MB by total CK and multiplying by 100. A value of 2.5% or higher suggests the CK-MB likely originates from heart muscle rather than skeletal muscle.

Despite its improved specificity, CK-MB still has limitations. It can be elevated in conditions like skeletal muscle injury, hypothyroidism, chronic kidney failure, and after strenuous exercise. These false positives require careful interpretation alongside clinical symptoms and other test results.

Cardiac troponins: the current gold standard 🔗

The discovery and implementation of cardiac troponin testing revolutionized heart attack diagnosis. Troponins are proteins that regulate muscle contraction in the heart. The troponin complex consists of three components: troponin C, troponin I, and troponin T. Among these, troponin I (TnI) and troponin T (TnT) are specific to heart muscle, making them superior diagnostic markers.

Why troponins are superior 🔗

Cardiac troponins have several advantages over older markers. First, they’re almost exclusively found in heart tissue, giving them exceptional specificity. Second, heart muscle contains 13 to 15 times more troponin per gram than CK-MB, which explains why troponins can detect even minor heart damage that CK-MB might miss. This higher sensitivity means troponins can identify smaller infarctions and provide earlier diagnosis.

Troponin levels begin rising within 2 to 4 hours after heart muscle damage, reach peak levels at 24 to 48 hours, and remain elevated for up to 10 to 14 days. This extended elevation window helps diagnose heart attacks in patients who seek medical attention days after their symptoms began. However, it also means troponins aren’t useful for detecting a second heart attack shortly after the first one, which is where CK-MB maintains its diagnostic value.

High-sensitivity troponin assays 🔗

Modern laboratories now use high-sensitivity troponin assays that can detect even tiny amounts of cardiac damage. These advanced tests allow doctors to rule out heart attacks much faster than before. Instead of waiting 6 to 12 hours for repeat testing, high-sensitivity assays enable accurate diagnosis within 2 to 3 hours. Some protocols even use 0-hour and 1-hour measurements to rapidly identify or exclude acute myocardial infarction.

Current clinical practice and guidelines 🔗

The European Society of Cardiology and American College of Cardiology recommend cardiac troponin as the only biomarker for diagnosing acute myocardial infarction. This recommendation stems from troponin’s superior sensitivity and specificity compared to all other markers. In fact, the definition of myocardial infarction now centers on troponin elevation combined with clinical symptoms or electrocardiogram changes.

Most hospitals now measure troponin levels at patient presentation and again at 2 to 3 hours (or sometimes up to 6 hours for older assays). A positive troponin test requires levels above the 99th percentile of healthy individuals. For patients with initial troponin elevation, a 20% rise in subsequent measurements confirms acute cardiac injury. In patients with low starting values, a 50% increase may be needed.

When other enzymes still matter 🔗

While troponins dominate modern cardiac care, other enzymes retain specific roles. CK-MB remains valuable for detecting reinfarction because it normalizes within 48 to 72 hours while troponins stay elevated for days. If a patient with elevated troponins develops new chest pain and their previously normal CK-MB suddenly rises, this pattern strongly suggests a new cardiac event.

Myoglobin, though non-specific, rises extremely rapidly after muscle damage. It can be detected within 1 to 2 hours of myocardial injury, peaks at 4 to 12 hours, and normalizes by 24 hours. Some emergency departments use myoglobin for very early risk stratification, though its lack of cardiac specificity limits widespread use. LDH now has limited application, mainly helping distinguish acute from subacute myocardial infarction in patients who present late with elevated troponins but normalized CK-MB levels.

Understanding the diagnostic timeline 🔗

The timing of enzyme release creates a diagnostic window for each marker. During the first 2 to 4 hours after symptoms begin, even high-sensitivity troponin may not detect all cases, which is why serial testing is essential. Between 4 and 12 hours, both CK-MB and troponin show good sensitivity. After 12 hours, troponin becomes increasingly reliable while other markers may already be declining.

This timeline explains why emergency departments typically don’t wait for cardiac marker results in patients with clear ST-elevation on their electrocardiogram. These patients need immediate treatment, and delaying therapy to await enzyme results could worsen outcomes. Cardiac markers serve as confirmation rather than the primary basis for emergency intervention.

Beyond myocardial infarction 🔗

Elevated cardiac enzymes don’t always mean a heart attack. Troponin levels can rise in many conditions including heart failure, myocarditis, pulmonary embolism, kidney failure, sepsis, and even strenuous exercise. This means doctors must interpret enzyme results within the full clinical context including symptoms, electrocardiogram findings, and imaging studies. A troponin elevation in isolation doesn’t automatically diagnose myocardial infarction, it indicates cardiac injury that requires investigation of the underlying cause.

The future of cardiac biomarkers 🔗

Research continues into novel biomarkers that might complement or improve upon current testing. Heart-type fatty acid-binding protein shows promise for very early detection, while other molecules help with risk stratification and prognosis. However, troponins currently represent the biochemical gold standard, and no emerging marker has demonstrated clear superiority.

The development of point-of-care testing devices allows rapid bedside troponin measurement, reducing turnaround times from hours to minutes. These advances enable faster decision-making in emergency settings, potentially improving patient outcomes through earlier intervention.

What do you think? How has understanding cardiac enzymes changed your perspective on heart attack diagnosis? Given the advances in troponin testing, should all healthcare facilities mandate high-sensitivity assays despite higher costs?

References

1. https://www.ncbi.nlm.nih.gov/books/NBK545216/
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC6340361/
3. https://atm.amegroups.org/article/view/10452/html
4. https://www.dovepress.com/biomarkers-in-acute-myocardial-infarction-current-perspectives-peer-reviewed-fulltext-article-VHRM
5. https://emedicine.medscape.com/article/811905-overview